AstraZeneca, the Anglo-Swedish pharma group involved in the US$7bn acquisition of Amylin this week, has the cash and appetite for further deals, according to interim chief executive Simon Lowth. Lowth told…
AstraZeneca hungry for acquisitions
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at firstname.lastname@example.org and we will call you to discuss.
Already a subscriber? Login here